ABSTRACT We investigated whether inhibition of nuclear factor-B (NFB) increases the efficacy of paclitaxel in in vitro
INTRODUCTION
Paclitaxel, a natural product originally isolated from the bark of Taxus brevifolia, has significant antitumor activity against several human cancers, particularly advanced ovarian and breast carcinomas (1, 2) . Unlike other antimicrotubule agents that interfere with tubulin polymerization, paclitaxel increases tubulin polymerization, stabilizes microtubules, and prevents tubulin depolymerization, ultimately causing tubulin bundling (3) (4) (5) . These effects of the drug are associated with cell cycle arrest in G 2 -M phase of the cell cycle, as well as cellular toxicity (5) (6) (7) . The inclusion of paclitaxel in the treatment of patients with newly diagnosed ovarian cancer has led to improved response rates and prolonged median survival compared with the results of prior therapeutic regimens (8) . Nevertheless, most of patients with advanced ovarian cancer are destined to relapse and develop resistance to initially active drugs such as paclitaxel (9) .
The sensitivity of cells to chemotherapeutic drug-induced apoptosis seems to depend on the balance between proapoptotic and antiapoptotic signals. Therefore, it is possible that antiapoptotic signals such as the phosphatidylinositol 3-kinase (PI3K)/ Akt survival cascade are involved in the sensitivity to chemotherapeutic drugs. We reported that Akt inactivation sensitizes human ovarian cancer cells to cisplatin (10) and paclitaxel (11) , suggesting that Akt inactivation could be a hallmark of the sensitivity of cells to some chemotherapeutic drugs. Possible mechanisms by which Akt promotes cell survival include phosphorylation and inactivation of the proapoptotic proteins BAD and caspase-9 (12, 13) . Akt also phosphorylates and inactivates the Forkhead transcription factors, resulting in reduced expression of the cell cycle inhibitor p27 Kip1 and the Fas ligand (14 -16) . Via the phosphorylation of IB kinase (IKK), Akt also activates nuclear factor-B (NFB), a transcription factor that has been implicated in cell survival (17, 18) .
NFB is activated in certain cancers and in response to chemotherapy and radiation. NFB normally resides in the cytoplasm as an inactivated form in a complex with inhibitor of NFB (IB␣). Phosphorylation of IB␣ by IKK promotes its degradation, allowing NFB to translocate to the nucleus and induce target genes (15, 16) . The transcriptional activation of genes associated with cell proliferation (19) , angiogenesis (20, 21) , metastasis (22, 23) , and suppression of apoptosis (24) seems to lie at the heart of the ability of NFB to promote oncogenesis (25) and cancer therapy resistance (26, 27) . Although it was proposed that NFB might be required for paclitaxel-induced cell death (28) , most reports suggest that paclitaxel-induced NFB activity mediates survival signals that counteract apoptosis (29 -31) . It has been reported that intrinsically or constitutively activated NFB may be critical in the development of drug resistance in cancer cells (29) . Therefore, several agents that are able to inhibit NFB function might be considered as an adjuvant approach in combination with paclitaxel for lung cancer (30) , prostate cancer (31), pancreatic cancer (32) , and breast cancer (33) .
These considerations led us to examine whether the status of NFB activity is involved in the sensitivity to paclitaxel in human ovarian cancer cells and whether agents that are able to inhibit NFB function might be considered as an adjuvant approach in combination with paclitaxel for ovarian cancer. In the present study, we show that BAY 11-7085, a known pharmacologic inhibitor of IB␣ phosphorylation (34), inhibits both basal and transient induction of IB␣ phosphorylation and NFB activity by paclitaxel for 3 hours. In addition, BAY 11-7085 enhances inhibition of NFB activity by paclitaxel for up to 24 hours and increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
EXPERIMENTAL PROCEDURES
Materials. Antiphospho-IKK␣ (Ser-180)/IKK␤ (Ser-181), anti-IKK␣, Antiphospho-IB␣, anti-IB␣, anticleaved poly(ADP-ribose) polymerase (PARP) and anti-X-linked inhibitor of apoptosis protein (anit-XIAP) antibodies were obtained from Cell Signaling Technology (Beverly, MA). Anti-matrix metalloproteinase-9 (anti-MMP-9) antibody was purchased from Chemicon (Temecula, CA). Anti-␤-actin antibody was purchased from Sigma. (St. Louis, MO). The IB␣ phosphorylation inhibitor BAY 11-7085 was purchased from Alexis Biochemicals (San Diego, CA). Enhanced chemiluminescence Western blotting detection reagents were obtained from Amersham (Arlington Heights, IL). The Cell Titer 96-well proliferation assay was obtained from Promega (Madison, WI).
Cell Cultures. The human ovarian papillary adenocarcinoma cell line Caov-3 was obtained from American Type Culture Collection (Rockville, MD). The cells were cultured at 37°C in DMEM with 10% fetal bovine serum in a watersaturated atmosphere of 95% air and 5% CO 2 .
Constructs. The NFB reporter plasmid (pElam-luc) was a kind gift from Dr. J. Cheng (University of South Florida College of Medicine; ref. 35) .
Proliferation Assay. Cell proliferation (36) was assessed by the addition of paclitaxel at the indicated concentrations for 48 hours 1 day after seeding test cells into 96-well plates. The number of surviving cells was determined 24 hours later by determination of A 490 of the dissolved formazan product after the addition of MTS {3-[4,5,dimethylthiazol-2-yl]-5-[3-carboxymethoxy-phenyl]-2-[4-sulfophenyl]-2H-tetrazolium, inner salt}for 1 hour as described by the manufacturer (Promega). All experiments were carried out in quadruplicate, and the viability was expressed as the ratio of the number of viable cells with paclitaxel treatment to that without treatment.
Western Blotting. Cells were incubated without serum for 16 hours and then treated with various agents. They were then washed twice with PBS and lysed in ice-cold HNTG buffer [50 mmol/L HEPES (pH 7.5), 150 mmol/L NaCl, 10% glycerol, 1% Triton X-100, 1.5 mmol/L MgCl 2 , 1 mmol/L EDTA, 10 mmol/L sodium PP I , 100 mol/L sodium orthovanadate, 100 mmol/L NaF, 10 g/mL aprotinin, 10 g/mL leupeptin, and 1 mmol/L phenylmethylsulfonyl fluoride; ref. 11). The lysates were centrifuged at 12,000 ϫ g at 4°C for 15 minutes, and the protein concentrations of the supernatants were determined with Bio-Rad protein assay reagent. Equal amounts of proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes. Blocking was carried out with 10% bovine serum albumin in 1ϫ Tris-buffered saline. Western blotting analyses were doned with various specific primary antibodies.
NFB Transcriptional Activation Analysis. Cells were seeded in 60-mm dishes and transfected with 2 g of NFB reporter plasmid (pElam-luc) for 24 hours with LipofectAMINE Plus (Life Technologies, Inc. Gaithersburg, MD) according to the manufacturer's protocol. Cells were treated with various agents, and then harvested and subjected to luciferase assays with the Luciferase Assay System (Promega) as described previously (37) . A plasmid expressing the bacterial ␤-galactosidase gene was also cotransfected in each experiment to serve as an internal control for transfection efficiency.
Assay of Invasion through Matrigel. Polyinylprolidone-free polycarbonate filters (8-m pore size; Chemotaxicell; KURABO, Osaka, Japan) were coated with a mixture of basement membrane components (Matrigel; 25 g/filter) and placed in modified Boyden chambers (38) . The cells (5 ϫ 10 4 ) were released from their culture dishes by brief exposure to EDTA (1 mmol/L), centrifuged, resuspended in 0.1% BSA-DMEM, and placed in the upper compartment of the Boyden chamber. Fibroblast-conditioned medium in the lower compartment served as a chemoattractant. After incubation for 24 hours at 37°C, the cells on the lower surface of the filter were fixed, stained with Mayer's hematoxylin solution, and enumerated with an ocular micrometer and counting at least 10 fields/filter. All of the experiments were independently done in triplicate.
Treatments In vivo. All of the procedures involving animals and their care in this study were approved by the animal care committee of Osaka University in accordance with institutional and Japanese government guidelines for animal experiments. Caov-3 cells were harvested in 0.25% trypsin-PBS-EDTA, washed once each with medium and PBS, and resuspended in PBS at 10 6 cells/200 L. One million Caov-3 cells were injected intraperitoneally into 5-week-old female nu/nu athymic mice (n ϭ 24). Two weeks after inoculation, one group of mice (n ϭ 6) was treated with BAY 11-7085 (5 mg/kg) 3 times weekly plus paclitaxel (20 mg/kg) 3 times weekly for 4 weeks. A second group of mice (n ϭ 6) was treated with BAY 11-7085 alone (5 mg/kg) 3 times weekly for 4 weeks. A third group (n ϭ 6) was treated with paclitaxel alone (20 mg/kg) 3 times weekly for 4 weeks. A fourth group of the mice (n ϭ 6) received vehicle (PBS) alone. An additional six mice inoculated with growth medium only served as a control group. Abdominal circumference and body weight were measured twice weekly. At the end of the experiment, mice underwent euthanasia with CO 2 . Final abdominal circumference and volume of ascites were measured, tumor tissue was excised, fixed in 4% paraformaldehyde, and embedded in paraffin. Paraffin sections (5 m) were used for histochemical analysis.
Statistics. Statistical analysis was done with one-way ANOVA followed by Fisher's least significant difference test, and P Ͻ 0.05 was considered significant. Data are expressed as the mean Ϯ SEM.
RESULTS
Effects of Paclitaxel on IKK Phosphorylation, IB␣ Phosphorylation, and NFB Activity. We first examined the effect of paclitaxel on the NFB signaling cascade. A putative Akt phosphorylation site (39) at amino acids 18 -23 in IKK␣ has been reported (15) . To examine whether phosphorylated Akt and IKK␣ were physically associated, cells were treated with (Fig. 1A , right) or without (Fig. 1A , left) paclitaxel for 3 hours, after which endogenous IKK␣ and phosphorylated Akt were immunoprecipitated (Fig. 1A ). Endogenous phosphorylated Akt and endogenous IKK␣ were coimmunoprecipitated from cells treated with paclitaxel, as in the case of cells stimulated with platelet-derived growth factor (16) . Next, we examined the effect of paclitaxel on the phosphorylation of Akt and the phosphorylation of IKK (Fig. 1B and C) . Cells were treated with the indicated concentrations of paclitaxel for 30 minutes ( (Fig. 1C ) and used to prepare lysates that were analyzed by Western blotting with antiphospho-IKK␣ (Ser-180)/IKK␤ (Ser-181), anti-IKK␣, antiphospho-Akt, or anti-Akt antibody. Although each expression of IKK␣ and Akt was not changed (Fig. 1B and C, iii and v), Caov-3 cells treated with paclitaxel showed a dosedependent (Fig. 1B) and a transient (Fig. 1C) increase in the phosphorylation of Akt (i and iv) and IKK (i and ii). Pretreatment with either of the PI3K inhibitors LY294002 (Fig. 1D,  Lane 3) or wortmannin (Fig. 1D, Lane 4) inhibited the paclitaxel-induced phosphorylation of both IKK (Fig. 1D, i and ii) and Akt (Fig. 1D, i and iv) .
We next examined whether paclitaxel induces the phosphorylation and degradation of IB␣ ( Fig. 2A) . Cells were treated with 200 nmol/L paclitaxel for the indicated times and used to prepare lysates that were analyzed by Western blotting with antiphospho-IB␣, anti-IB␣, or anti-␤-actin antibody. Although the expression of ␤-actin was not changed ( Fig. 2A,  iv) , paclitaxel-stimulated Caov-3 cells showed a transient increase in the phosphorylation of IB␣ (Fig. 2A, i and ii) and in its subsequent degradation ( Fig. 2A, i and iii) . Pretreatment with either LY294002 (Fig. 2B, Lane 3) or wortmannin (Fig. 2B , Lane 4) inhibited both the paclitaxel-induced phosphorylation of IB␣ (Fig. 2B, i and ii) and the degradation of IB␣ (Fig. 2B,  i and iii) .
To assess NFB activity, cells were transfected with an NFB-luciferase reporter plasmid and treated with 200 nmol/L paclitaxel for the indicated times. Paclitaxel caused a transient increase in NFB activity lasting 2 to 4 hours, followed by a decrease in NFB activity thereafter (Fig. 2C) . Pretreatment with LY294002 inhibited the transient up-regulation of NFB activity by paclitaxel for 3 hours (Fig. 2D) . Collectively, these results indicate that paclitaxel transiently induces phosphorylation of IKK and IB␣ as well as activation of NFB via a PI3K/Akt cascade, followed by the decrease in NFB activity thereafter. As we reported previously (11) , similar findings were also detected in other ovarian cancer cell lines (data not shown). We first confirmed that treatment with BAY 11-7085 attenuated both basal and transient induction of IB␣ phosphorylation by paclitaxel (Fig. 3A) . Treatment with BAY 11-7085 inhibited the transient induction of NFB activity by paclitaxel for 3 hours (Fig. 3B, i) and enhanced the inhibition of NFB activity by paclitaxel for 24 hours (Fig. 3B, ii) . Whereas either treatment with paclitaxel for 24 hours (Fig. 3C, right) or treatment with BAY 11-7085 for 24 hours (Fig. 3C, left) inhibited cell viability, cotreatment with paclitaxel plus BAY 11-7085 for 24 hours further enhanced the inhibitory effects on cell viability (Fig. 3C,  right) .
We further examined the effect of treatment with paclitaxel for 24 hours and treatment with BAY 11-7085 for 24 hours alone and in combination on apoptosis by Western blotting with anticleaved PARP antibody (Fig. 3D) . Paclitaxel induced cleavage of PARP. BAY 11-7085 seemed to enhance the ability of paclitaxel to induce cleavage of PARP, whereas the expression of ␤-actin was not changed by any of these treatments.
Effect of Inhibition of NFB Activity on PaclitaxelInduced Attenuation of the Expression of Survival Genes. NFB regulates the expression of a number of antiapoptotic genes (40 -42) . Among them are the family of inhibitor of apoptosis proteins, which play a central role in repressing caspase-mediated cell death. It was reported that cisplatin inhibits the expression of XIAP (43, 44) and down-regulation of XIAP induces apoptosis and increases paclitaxel sensitivity (45-47), suggesting that XIAP is a determinant of paclitaxel sensitivity in ovarian cancer. Therefore, we examined the effect of paclitaxel and BAY 11-7085 alone and in combination on the expression of XIAP. Although paclitaxel treatment alone had no effect on XIAP expression under these conditions, BAY 11-7085 partially attenuated the expression of XIAP, and cotreatment with paclitaxel plus BAY 11-7085 almost completely abolished the expression of XIAP (Fig. 4) .
Effect of Inhibition of NFB Activity on PaclitaxelInduced Attenuation of Invasion of Caov-3 Cells through Matrigel. Because it was reported that NFB is involved in invasiveness and metastatic properties (48), we examined the effects of paclitaxel and BAY 11-7085 alone and in combination on the invasion of Caov-3 cells through Matrigel. Whereas either paclitaxel or BAY 11-7085 partially inhibited cell invasion through Matrigel, cotreatment with paclitaxel plus BAY 11-7085 almost completely inhibited cell invasion through Matrigel (Fig. 5A) .
To confirm that inhibitory effects on invasion are not secondary to the cells simply being nonviable, the expression of MMP-9 was examined. Although either paclitaxel or BAY 11-7085 partially inhibited MMP-9 expression, cotreatment with paclitaxel plus BAY 11-7085 almost completely inhibited MMP-9 expression (Fig. 5B, i and ii) . The expression of ␤-actin was not changed by any of these treatments (Fig. 5B, iii) .
Effect of BAY 11-7085 on Paclitaxel-Induced Inhibition of Intraabdominal Dissemination of Ovarian Cancer.
Ovarian cancer is initially clinically silent, and half of patients are first detected at an advanced stage with ascites and peritoneal dissemination (28) . Because peritoneal dissemination is the main process of progression in ovarian cancer, and the amount of ascitic fluid and the size of the disseminated tumor are correlated with the patient's prognosis (49) , controlling ascitic fluid and peritoneal dissemination are crucial in the therapy of ovarian cancer. We therefore examined the effect of paclitaxel and BAY 11-7085 alone and in combination on the control of intraabdominal dissemination of ovarian cancer and ascites formation to assess whether combination therapy would increase the therapeutic efficacy of each agent. Athymic nude mice were inoculated intraperitoneally with Caov-3 cells or growth me- Fig. 6A . The abdominal circumference was measured (Fig. 6B) , and the volume of ascites was also measured at autopsy (Fig. 6C ). Both abdominal circumference and volume of ascites were significantly higher in athymic nude mice inoculated intraperitoneally with Caov-3 cells than in athymic nude mice inoculated intraperitoneally with growth medium. Pathologic examination was done to determine the extent of intraabdominal dissemination at autopsy. Intra-abdominal dissemination was clearly detected in athymic nude mice inoculated intraperitoneally with Caov-3 cells followed by treatment with vehicle (Fig. 7A) , and the intraabdominal dissemination was shown by histologic assessment to consist of mucinous cystoadenocarcinoma (Fig. 7B) , which is consistent with Caov-3 cells. Paclitaxel alone (Fig. 6B  and C, b) or BAY 11-7085 alone ( Fig. 6B and C, c) significantly diminished both the abdominal circumference and the volume of ascites compared with those in the vehicle control. The combination of paclitaxel ϩ BAY 11-7085 ( Fig. 6B and C, d) further enhanced the inhibitory effects on the abdominal circumference and the production of ascites. Paclitaxel alone or BAY 11-7085 alone also diminished the extent of intraabdominal dissemination; combination of paclitaxel ϩ BAY 11-7085 further enhanced the inhibitory effect on intraabdominal dissemination (data not shown). These results suggest that combination therapy of paclitaxel with BAY 11-7085 would increase the therapeutic efficacy of paclitaxel.
DISCUSSION
The novel finding in this study is that an NFB inhibitor, which enhanced paclitaxel-induced inhibition of IB␣ phosphorylation and NFB activity, increased the efficacy of paclitaxel in both in vitro and in vivo ovarian cancer models. Although adjuvant approaches in combination with paclitaxel have been reported for lung cancer (30) , prostate cancer (31), pancreatic cancer (32) , and breast cancer (33) , there have been no reports about an adjuvant approach in combination with paclitaxel for ovarian cancer. In addition, in vitro models were used in previous reports, and there have been no reports using in vivo models.
It was previously proposed that NFB might be required for paclitaxel-induced cell death (28) . Thus, although NFB is a transcription factor that has been implicated in cell survival (17, 18) , there is a possibility that the function of NFB depends on tumor type. However, most reports suggest that paclitaxelinduced NFB activity mediates survival signals that counteract apoptosis (29 -31) .
We reported that Akt inactivation and inhibition of BAD phosphorylation sensitize human ovarian cancer cells to cisplatin (10) and paclitaxel (11) . In addition, we showed recently that inhibition of Forkhead phosphorylation sensitizes human ovarian cancer cells to cisplatin (50) . Although NFB is a substrate of Akt, like BAD and Forkhead, NFB activation is involved in angiogenesis (20, 21) and metastasis (22, 23) as well as in suppression of apoptosis. Therefore, NFB inhibitors might increase the efficacy of chemotherapy against both primary and metastatic lesions. It was reported that NFB inhibitors induce adhesion-dependent colon cancer apoptosis (51) . We showed in this study that treatment of athymic mice with BAY 11-7085 enhances the ability of paclitaxel to inhibit tumor implantation into the liver and peritoneum (Fig. 7) . In addition, BAY 11-7085 increased the ability of paclitaxel to inhibit both cell proliferation in an MTS assay (Fig. 3C) and cellular invasion in an in vitro invasion assay (Fig. 5A) . Thus, NFB inhibitors might increase the efficiency with which paclitaxel inhibits both primary and metastatic lesions. Glycogen synthase kinase 3␣ (52) and endothelial nitric oxide synthase (53, 54) are also Akt substrates, and Akt is thus also involved in metabolic processes and vessel dilation, respectively. Therefore, it is possible that inhibition of PI3K/Akt activation is not a safe strategy for preventing chemoresistance. Accordingly, NFB inhibitors might be more useful for sensitization to chemotherapeutic drugs than agents that are able to inhibit PI3K/Akt activity. Moreover, we also showed that the signaling cascade of NFB is involved in the mechanism of maintaining the cell viability after cisplatin treatment of ovarian cancer cells (55) , as in the case of paclitaxel. Thus, because NFB inhibitors might augment the effects of both cisplatin and paclitaxel, which together constitute the first line regimen of treatment for ovarian cancer, the combination of NFB inhibitors with cisplatin and paclitaxel might be useful for molecularly targeted therapy.
How do NFB inhibitors cause the inhibition of growth of human ovarian cancer cells? It was reported that NFB inhibitors reduced the expression of survival genes regulated by NFB, such as c-IAP-2, TRAF-1, TRAF-2, XIAP, or IEX-1L (41, 42) . We also showed that NFB inhibitors inhibited the expression of survival genes in human ovarian cancer cells (Fig.  4) . The fact that NFB mediates the expression of multiple survival genes makes it an important and rational target for cancer chemotherapy.
Activation of NFB via phosphorylation of an inhibitor protein (IB␣) leads to degradation of IB␣ through the ubiquitin-proteasome pathway. Inhibition of IB␣ degradation by proteasome inhibitors keeps NFB in the cytoplasm, thereby preventing it from acting on nuclear DNA (56, 57) . PS-341, which is a potent boronic acid dipeptide that is highly selective for proteasome inhibition, can be systemically administered clinically (58) . PS-341 has been shown to enhance apoptotic response to chemotherapy in a variety of in vitro and in vivo models (59 -62) . A phase I trial of PS-341 and carboplatin in recurrent ovarian cancer is currently ongoing (63) . A phase II trial of PS-341 for the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer (GOG 146-N) is also being conducted. It was also reported that proteasome inhibitor 1 enhances paclitaxel-induced apoptosis in a human lung adenocarcinoma cell line (30) . This is the first report that an NFB inhibitor sensitizes human ovarian cancer cells to the effect of paclitaxel and the first to suggest that future clinical trials designed to examine the effect of NFB inhibitors on the sensitivity to paclitaxel are warranted. 
